Capital BlueCross HCT Coverage Update

Coverage Criteria for Hematopoietic Cell Transplantation in NHL

Medical necessity and investigational criteria

Covered when listed conditions for specific NHL subtypes and scenarios are met:

Aggressive B-cell NHL (except mantle cell)

Indications: (1) Salvage therapy for individuals who do not achieve a complete remission after first-line treatment (induction) with a full course of standard-dose chemotherapy; (2) To achieve or consolidate a complete remission for those in a chemo-sensitive first or subsequent relapse; (3) To consolidate a first complete remission in individuals with diffuse large B-cell lymphoma with an age-adjusted International Prognostic Index score predicting high- or high-intermediate risk of relapse.

Mantle cell lymphoma: Autologous HCT to consolidate a first remission is medically necessary; allogeneic HCT (myeloablative or reduced-intensity conditioning) may be medically necessary as salvage therapy.

Mantle cell investigational: Autologous HCT as salvage therapy and allogeneic HCT to consolidate a first remission are investigational for mantle cell lymphoma.

Indolent B-cell NHL: Autologous HCT or allogeneic HCT with myeloablative conditioning may be considered medically necessary as salvage therapy for individuals who do not achieve a complete remission after first-line induction with a full course of standard-dose chemotherapy or to achieve/consolidate a complete remission for chemo-sensitive relapses (including transformed disease).

Initial therapy exclusion: Autologous or allogeneic HCT is investigational as initial therapy without a full course of standard-dose induction chemotherapy for any NHL.

Diffuse large B-cell low-risk: Autologous or allogeneic HCT to consolidate a first complete remission is investigational for individuals with diffuse large B-cell lymphoma whose IPI predicts low- or low-intermediate risk of relapse.

Indolent NHL first CR: Autologous or allogeneic HCT to consolidate a first complete remission for indolent B-cell NHL subtypes is investigational.

Peripheral T-cell and NK-cell neoplasms: Autologous HCT may be medically necessary to consolidate a first complete remission in high-risk subtypes; autologous or allogeneic HCT (myeloablative or reduced-intensity conditioning) may be medically necessary as salvage therapy; allogeneic HCT to consolidate a first remission is investigational.

See Policy Guidelines for high-risk subtype definitions.

Hepatosplenic T-cell lymphoma: Allogeneic HCT may be considered medically necessary to consolidate a first complete or partial response; autologous HCT may be considered medically necessary to consolidate a first response if a suitable donor is not available or the patient is ineligible for allogeneic HCT; initial therapy with HCT is investigational.

Reduced-intensity conditioning allogeneic HCT may be considered medically necessary for individuals who meet criteria for allogeneic HCT but do not qualify for myeloablative conditioning (e.g., older age or significant comorbidities).

Autologous HCT — indolent B-cell NHL

Policy conclusions from rationale summary regarding autologous HCT in indolent and aggressive B-cell NHL:

Autologous HCT for indolent B-cell NHL as first-line: Randomized trials have not shown a survival advantage with autologous HCT as first-line therapy for indolent B-cell lymphomas.

Insufficient evidence to support routine first-line use; not routinely covered as first-line based on evidence summary

Autologous HCT for relapsed indolent B-cell NHL: Randomized studies have shown a survival benefit for autologous HCT in relapsed indolent B-cell NHL.

Evidence sufficient to support HCT for relapsed indolent B-cell NHL

Autologous HCT — aggressive B-cell NHL

Policy conclusions for consolidation and relapsed aggressive B-cell NHL:

Consolidation autologous HCT after first complete remission: Some randomized trials show overall survival benefit in patients at high- or high-intermediate risk of relapse when autologous HCT consolidates a first complete remission (age-adjusted IPI used to define risk).high- or high-intermediate IPI

May be covered selectively for patients meeting high-risk criteria

Autologous HCT for relapsed aggressive B-cell NHL: Randomized studies have shown an overall survival benefit with autologous HCT in relapsed aggressive B-cell lymphomas.

Evidence supports coverage for relapsed aggressive B-cell NHL

Comparative evidence

Comparative outcomes and evidentiary stance:

Allogeneic vs autologous HCT for relapsed/refractory B-cell NHL: A retrospective study comparing autologous and allogeneic HCT for relapsed or refractory B-cell NHL favored autologous HCT, supporting an autologous HCT preference in some relapsed settings; individual assessment required.

Supports autologous HCT preference in some relapsed settings; individual assessment required

Indolent B-cell NHL

Autologous HCT in B-cell NHL

Indolent B-cell NHL - first-line autologous HCT: Randomized trials have not demonstrated a survival advantage with autologous HCT as first-line therapy for indolent B-cell lymphomas; evidence is insufficient to determine net health outcome.

See rationale summary.

Aggressive B-cell NHL (excluding MCL)

Autologous HCT consolidation in aggressive B-cell NHL (excluding MCL)

Aggressive B-cell NHL consolidation: Randomized trials offer conflicting results; some data show overall survival benefit in high- or high-intermediate risk patients when HCT consolidates a first complete remission; HCT in relapsed disease has shown OS benefit in randomized studies.

Evidence sufficient for meaningful improvement in net health outcome in specified settings.

Tandem HCT

Tandem autologous and allogeneic HCT

ref":"b0_6","title":"Tandem HCT"},{

citations":["38"],"intro":"Mantle cell lymphoma (MCL)","nodes":["{\"operator\":\"any\",\"n\":null,\"label\":\"MCL - autologous HCT\",\"text\":\"Case series and randomized trials have shown long-term disease control with autologous HCT (with rituximab) to consolidate a first remission; autologous HCT in relapsed MCL has not demonstrated improved outcomes.\",\"threshold\":\"\",\"note\":\"Allogeneic HCT has shown prolonged disease control in relapsed/refractory settings; evidence overall insufficient to determine net health outcome.\",\"children\":[]}"] ,"ref":"b0_7","title":"Mantle cell lymphoma"},{"citations":["39"],"intro":"Peripheral T-cell lymphoma (PTCL)","nodes":["{\"operator\":\"any\",\"n\":null,\"label\":\"PTCL - HCT role\",\"text\":\"The role of HCT in PTCL is not well-defined; available studies are limited and heterogeneous. Phase 2 data suggest autologous HCT consolidation offers best survival for high-risk features; HCT in relapsed/refractory PTCL may improve outcomes and is supported in salvage settings.\",\"threshold\":\"\",\"note\":\"Evidence sufficient for meaningful improvement in net health outcome in selected salvage/first-line consolidation scenarios.\",\"children\":[]}"] ,"ref":"b0_8","title":"Peripheral T-cell lymphoma"},{"citations":["40"],"intro":"Hepatosplenic T-cell lymphoma (HSTCL)","nodes":["{\"operator\":\"all\",\"n\":null,\"label\":\"HSTCL - consolidation HCT\",\"text\":\"Observational studies and two patient-level meta-analyses found that consolidation HCT (autologous or allogeneic) after first response improves survival; achieving complete response at time of autologous HCT is associated with improved overall survival.\",\"threshold\":\"\",\"note\":\"Evidence sufficient for improved net health outcome.\",\"children\":[]}"] ,"ref":"b0_9","title":"Hepatosplenic T-cell lymphoma"},{"citations":["2","3"],"intro":"Tandem transplants are considered investigational for any stage, grade, or subtype of NHL.","nodes":["{\"operator\":\"all\",\"n\":null,\"label\":\"Investigational - Tandem transplants\",\"text\":\"Tandem autologous and allogeneic transplants are investigational for all NHL subtypes due to insufficient evidence from randomized trials.\",\"threshold\":\"\",\"note\":\"Requests for tandem transplants may be denied as investigational.\",\"children\":[]}"] ,"ref":"b0_10","title":"Tandem transplants investigational"},{"citations":["1","6"],"intro":"Salvage — top-level node","nodes":["{\"operator\":\"any\",\"n\":null,\"label\":\"Salvage or consolidation indication\",\"text\":\"Salvage therapy is defined as therapy given for refractory or relapsed disease; HCT may be medically necessary as salvage for individuals who do not achieve CR with first-line induction chemotherapy or who relapse after prior response.\",\"threshold\":\"\",\"note\":\"Document prior lines of therapy and response (chemosensitive vs refractory) in prior authorization.\",\"children\":[]}"] ,"ref":"b1_0","title":"salvage — top-level node"},{"citations":["1","2"],"intro":"Salvage — top-level node","nodes":["{\"operator\":\"any\",\"n\":null,\"label\":\"Salvage criteria\",\"text\":\"Autologous HCT or allogeneic HCT may be considered medically necessary as salvage therapy for indolent and aggressive B-cell NHL subtypes when disease is refractory to or relapsed after standard induction chemotherapy.\",\"threshold\":\"\",\"note\":\"Prior authorization should confirm prior chemotherapy regimens and response.\",\"children\":[]}"] ,"ref":"b1_1","title":"salvage — top-level node"},{"citations":["37","26"],"intro":"First-line — top-level node","nodes":["{\"operator\":\"any\",\"n\":null,\"label\":\"First-line consolidation criteria\",\"text\":\"Autologous HCT may be considered to consolidate a first complete remission in certain aggressive B-cell lymphomas (e.g., DLBCL) for patients with high- or high-intermediate IPI; routine first-line autologous HCT for indolent B-cell NHL is not supported by randomized evidence and is not routinely covered.\",\"threshold\":\"high- or high-intermediate IPI\",\"note\":\"Document IPI and staging per policy guidelines.\",\"children\":[]}"] ,"ref":"b1_2","title":"first-line — top-level node"},{"citations":["37","38","39","40"],"intro":"First-line — top-level node","nodes":["{\"operator\":\"any\",\"n\":null,\"label\":\"First-line consolidation and evidence by subtype\",\"text\":\"Evidence supports autologous HCT consolidation in selected first-line scenarios for MCL and some aggressive subtypes; for PTCL and HSTCL, HCT consolidation may be considered per subtype-specific data.\",\"threshold\":\"\",\"note\":\"See subtype-specific criteria and guideline references.\",\"children\":[]}"] ,"ref":"b1_3","title":"first-line — top-level node"},{"citations":["37","39"],"intro":"Salvage — top-level node","nodes":["{\"operator\":\"any\",\"n\":null,\"label\":\"PTCL salvage criteria\",\"text\":\"In peripheral T-cell lymphoma, HCT (autologous or allogeneic) may be considered medically necessary in the salvage setting and can improve outcomes; available evidence is limited but supportive for salvage use.\",\"threshold\":\"\",\"note\":\"Document refractory vs relapsed status and prior therapies.\",\"children\":[]}"] ,"ref":"b1_4","title":"salvage — top-level node"},{"citations":["37","39","59","62"],"intro":"Salvage — top-level node","nodes":["{\"operator\":\"any\",\"n\":null,\"label\":\"Salvage HCT general criteria\",\"text\":\"Autologous HCT has demonstrated overall survival benefit in relapsed aggressive B-cell NHL and is an accepted salvage option; allogeneic HCT may be considered in selected relapsed/refractory cases.\",\"threshold\":\"\",\"note\":\"Retrospective comparisons have favored autologous HCT in some relapsed settings.\",\"children\":[]}"] ,"ref":"b1_5","title":"salvage — top-level node"},{"citations":["54","55","57","59"],"intro":"Salvage — top-level node (evidence citations)","nodes":["{\"operator\":\"all\",\"n\":null,\"label\":\"Key evidence supporting salvage and tandem approaches\",\"text\":\"Selected references include randomized trials and nonrandomized series reporting outcomes after autologous and tandem high-dose regimens; however, tandem regimens lack randomized data and evidence is limited.\",\"threshold\":\"\",\"note\":\"See references for trial-specific inclusion criteria and outcomes.\",\"children\":[]}"] ,"ref":"b1_6","title":"salvage — top-level node (evidence citations)"}]}{

Mantle cell lymphoma

Mantle cell lymphoma (MCL)

MCL - autologous HCT: Case series and randomized trials have shown long-term disease control with autologous HCT (with rituximab) to consolidate a first remission; autologous HCT in relapsed MCL has not demonstrated improved outcomes.

Allogeneic HCT has shown prolonged disease control in relapsed/refractory settings; evidence overall insufficient to determine net health outcome.

Peripheral T-cell lymphoma

Peripheral T-cell lymphoma (PTCL)

PTCL - HCT role: The role of HCT in PTCL is not well-defined; available studies are limited and heterogeneous. Phase 2 data suggest autologous HCT consolidation offers best survival for high-risk features; HCT in relapsed/refractory PTCL may improve outcomes and is supported in salvage settings.

Evidence sufficient for meaningful improvement in net health outcome in selected salvage/first-line consolidation scenarios.

Hepatosplenic T-cell lymphoma

Hepatosplenic T-cell lymphoma (HSTCL)

HSTCL - consolidation HCT: Observational studies and two patient-level meta-analyses found that consolidation HCT (autologous or allogeneic) after first response improves survival; achieving complete response at time of autologous HCT is associated with improved overall survival.

Evidence sufficient for improved net health outcome.

Tandem autologous → allogeneic hematopoietic cell transplantation (HCT) for non-Hodgkin lymphoma is considered investigational. The policy states that no randomized trials exist and the published evidence is limited to small nonrandomized series, so conclusions about benefit cannot be made and the evidence is insufficient to determine effects on health outcomes.

Randomized trials and systematic reviews have not demonstrated a survival advantage for autologous HCT as first-line therapy in indolent B-cell non-Hodgkin lymphomas. By contrast, randomized studies have shown a survival benefit when autologous HCT is used in the relapsed setting. Therefore routine use of autologous HCT as initial or consolidation therapy in first remission for indolent B-cell lymphomas is not supported by the evidence summarized in this policy.

Mantle cell lymphoma (MCL) is addressed separately from other aggressive B-cell non-Hodgkin lymphomas in this policy. The document summarizes MCL-specific data — including case series and randomized trials — that support autologous HCT (with rituximab) to consolidate a first remission, while noting different outcomes and recommendations for relapsed disease and allogeneic HCT compared with other aggressive B-cell subtypes.

No explicit additional exclusion criteria beyond those stated in the policy text were identified in the cited document history or policy history entries.

The policy explicitly considers autologous or allogeneic HCT as initial therapy (i.e., without completion of a full course of standard-dose induction chemotherapy) for any NHL subtype to be investigational due to insufficient evidence to support this use.

For indolent B-cell non-Hodgkin lymphomas, the rationale summary indicates that autologous HCT used as first-line therapy has not demonstrated a survival benefit in randomized trials, whereas autologous HCT for relapsed disease has shown a survival advantage. This distinction underpins the policy's more restrictive stance on routine first-line autologous HCT for indolent subtypes.

Evidence summary: randomized trials of autologous HCT in indolent B-cell lymphomas have not shown improvement in overall survival when used as first-line therapy; randomized and observational studies instead support benefit in relapsed disease. The policy concludes the evidence is insufficient to determine net health benefit for routine first-line autologous HCT in these patients.

The document review and policy history do not contain explicit phrasing that uses the term "not medically necessary" in these cited chunks; the policy uses investigational language and exclusion statements to delineate non-supported indications.

Line of Therapy Considerations

salvage — top-level node

Salvage — top-level node

Salvage or consolidation indication: Salvage therapy is defined as therapy given for refractory or relapsed disease; HCT may be medically necessary as salvage for individuals who do not achieve CR with first-line induction chemotherapy or who relapse after prior response.

Document prior lines of therapy and response (chemosensitive vs refractory) in prior authorization.

salvage — top-level node

Salvage — top-level node

Salvage criteria: Autologous HCT or allogeneic HCT may be considered medically necessary as salvage therapy for indolent and aggressive B-cell NHL subtypes when disease is refractory to or relapsed after standard induction chemotherapy.

Prior authorization should confirm prior chemotherapy regimens and response.

first-line — top-level node

Provider Requirements and Authorization Guidance

Prior Authorization

Prior Authorization and Provider Responsibilities

Prior authorization is required to confirm the indication for hematopoietic cell transplantation (HCT). Document prior lines of therapy and the response to each (including whether a full course of standard-dose induction chemotherapy was completed), and confirm that induction chemotherapy was completed prior to autologous HCT when applicable. Coverage determinations require review of medical necessity and the member's benefit plan; presence of procedure codes does not guarantee coverage.

Prior authorization required to confirm indication for autologous or allogeneic HCT (e.g., relapsed indolent B-cell NHL; consolidation after chemo-sensitive relapse).
Document prior therapies and response status (lines of therapy, date(s), regimen(s), best response: CR/PR/stable/progressive).
Ensure induction chemotherapy was completed before autologous HCT when indicated.
Medical necessity and member benefits determine final authorization and payment — contact payer for eligibility and benefit limits.
No step therapy requirements specified in this policy.
Prior authorization guidance references clinical guidelines (e.g., NCCN, ASTCT/CIBMTR/EBMT) and the policy rationale; use these as clinical context for authorization decisions.
Coverage risk: Evidence summaries indicate autologous HCT as first-line therapy for indolent B-cell NHL may be non-covered; relapsed/chemo-sensitive indications have stronger evidence supporting benefit.

Procedure and Diagnosis Codes

Covered when Medically Necessary (procedure codes)CPTCovered

38210	Procedure Codes
38211	Procedures related to hematopoietic stem cell transplantation (listed mapping in coding list)
38204	Procedure code mapping indicated in coding list
38205	Procedure code mapping indicated in coding list
38206	Procedure code mapping indicated in coding list
38207	Procedure code mapping indicated in coding list
38208	Procedure code mapping indicated in coding list
38209	Procedure code mapping indicated in coding list
38241	Procedure code listed (entry appears incomplete in document)

Referenced ICD-10 changesICD-10

C84.7A

ICD-10 code referenced as added previously (new code added effective 10/01/2021)

MCL IPI risk group cutoffs

MCL IPI low-risk0-3 points (5-year overall survival ~60%)

MCL IPI intermediate-risk4-5 points (median overall survival ~51 months)

MCL IPI high-risk6-11 points (median overall survival ~29 months)

IPI / Follicular Lymphoma IPI risk group cutoffs

IPI risk groups (DLBCL)0-1 = low; 2 = low‑intermediate; 3 = high‑intermediate; 4-5 = high

Age‑adjusted IPI (younger patients)0 = low; 1 = low‑intermediate; 2 = high‑intermediate; 3 = high

Regimens and Sequencing

Regimen	Context / Indication	Policy note
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT)	Used as consolidation for frontline or as salvage therapy in high-risk aggressive NHL subtypes, including mantle cell lymphoma (MCL) frontline consolidation with rituximab-containing regimens; also used for relapsed chemosensitive disease.	Supported by nonrandomized and randomized trials in selected high-risk or relapsed settings; considered an appropriate consolidated strategy for MCL first remission and for selected aggressive B-cell lymphomas with high/high-intermediate IPI.
Tandem high‑dose chemotherapy regimens (sequential multiple ASCT courses)	Investigated in small pilot and single-arm studies for poor‑risk lymphoma or early-intensified strategies; examples include pilot tandem regimens for poor‑risk patients.	Evidence limited to nonrandomized pilot studies; insufficient randomized data to establish improved net health outcomes—tandem approaches are considered investigational by the policy.
Sequential autologous followed by reduced‑intensity conditioning (RIC) allogeneic HCT	Used in protocols where ASCT is followed by RIC allogeneic HCT (autologous→RIC‑allo) for poor‑risk or relapsed disease; reported in pediatric/young adult series and small cohort studies.	Published series report feasibility and potential prolonged disease control, but no randomized trials; policy notes evidence is insufficient to conclude benefit for sequential autologous→RIC‑allo approaches in NHL.

Definitions and Background

Hematopoietic cell transplantation (HCT) uses autologous or allogeneic hematopoietic stem cells to restore marrow and immune function after marrow‑ablative or reduced‑intensity cytotoxic therapy. Allogeneic HCT requires donor HLA compatibility and confers a graft‑versus‑tumor effect but carries the risk of graft‑versus‑host disease; autologous HCT uses the patient’s own harvested stem cells and is commonly employed to consolidate remission in chemosensitive disease. Reduced‑intensity conditioning (RIC) regimens are available for patients who meet indications for allogeneic HCT but are ineligible for myeloablative conditioning (for example, due to age or comorbidities).

Reduced-intensity conditioning (RIC) definition

DefinitionPretransplant regimens using lower doses or less intense cytotoxic drugs or radiotherapy intended to be nonmyeloablative to balance relapse risk and treatment‑related mortality

Typical useOption for individuals eligible for allo‑HCT who do not qualify for myeloablative conditioning due to age (typically >55 years) or comorbidities

GoalReduce early treatment‑related morbidity and mortality while allowing graft‑versus‑malignancy effect to develop

Clinical Background and Epidemiology

Clinical context: The policy frames HCT in NHL around two typical uses — consolidation of remission and salvage therapy after relapse or refractory disease. For aggressive B‑cell NHL (excluding MCL), autologous HCT can be considered to consolidate a first CR in patients at high or high‑intermediate risk of relapse (based on prognostic indices), and autologous HCT shows survival benefit in relapsed disease. For indolent B‑cell NHL, autologous HCT is supported for relapsed chemosensitive disease but lacks randomized data showing a first‑line survival benefit. For certain T‑cell subtypes such as peripheral T‑cell or hepatosplenic T‑cell lymphoma, the role of autologous and allogeneic HCT varies by subtype and response, with allogeneic HCT often favored for consolidation in HSTCL and RIC considered where full myeloablative conditioning is not appropriate.

Key Metrics and Epidemiology

Policy Revision History

2026-01-28Consensus reviewLatest

Consensus review — no change to policy intent; rationale and references updated.

2025-06-24Administrative update

Administrative update removing Benefit Variations section and updating the Disclaimer.

2025-02-20Consensus review

Hematopoietic Cell Transplantation for Non-Hodgkin Lymphomas

Sign up for Capital Bluecross Policy MP 9.042 alerts